[go: up one dir, main page]

ATE323756T1 - Natürliche killerzelllinien und verfahren zu ihrer verwendung - Google Patents

Natürliche killerzelllinien und verfahren zu ihrer verwendung

Info

Publication number
ATE323756T1
ATE323756T1 AT98920012T AT98920012T ATE323756T1 AT E323756 T1 ATE323756 T1 AT E323756T1 AT 98920012 T AT98920012 T AT 98920012T AT 98920012 T AT98920012 T AT 98920012T AT E323756 T1 ATE323756 T1 AT E323756T1
Authority
AT
Austria
Prior art keywords
cell
cytokine
natural killer
vivo
mammal
Prior art date
Application number
AT98920012T
Other languages
English (en)
Inventor
Hans Klingemann
Original Assignee
Hans Klingemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27366772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE323756(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hans Klingemann filed Critical Hans Klingemann
Application granted granted Critical
Publication of ATE323756T1 publication Critical patent/ATE323756T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C12N5/0093—Purging against cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT98920012T 1997-04-30 1998-04-30 Natürliche killerzelllinien und verfahren zu ihrer verwendung ATE323756T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4588597P 1997-04-30 1997-04-30
US9716398P 1998-08-19 1998-08-19
US40391099A 1999-10-27 1999-10-27
US10/008,955 US10138462B2 (en) 1997-04-30 2001-12-07 Natural killer cell lines and methods of use

Publications (1)

Publication Number Publication Date
ATE323756T1 true ATE323756T1 (de) 2006-05-15

Family

ID=27366772

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98920012T ATE323756T1 (de) 1997-04-30 1998-04-30 Natürliche killerzelllinien und verfahren zu ihrer verwendung

Country Status (7)

Country Link
US (5) US10138462B2 (de)
EP (2) EP1690927A1 (de)
AT (1) ATE323756T1 (de)
AU (1) AU7267398A (de)
DE (1) DE69834257T2 (de)
ES (1) ES2263205T3 (de)
WO (1) WO1998049268A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511830B1 (en) * 1997-09-26 2003-01-28 Kyowa, Hakko Kogyo Co., Ltd. Killer T cell receptor recognizing human immunodeficiency virus
DE10121113A1 (de) * 2001-04-28 2002-10-31 Gabriele Pecher Genmodifizierte YT Zelllinie und ihre Verwendung
WO2005018121A1 (en) * 2003-08-04 2005-02-24 Thomson Licensing S.A. Adaptive frame synchronization in a universal mobile telephone system receiver
JP2008505071A (ja) * 2004-07-02 2008-02-21 アヴァリス・アクチエボラーグ 細胞を遺伝学的に活性化する方法、および、該細胞の使用
ATE443084T1 (de) 2004-07-10 2009-10-15 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
EP1863905B1 (de) * 2005-03-17 2016-01-20 UCL Business PLC Methode zur aktivierung natürlicher killerzellen durch tumorzellpräparationen in vitro
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
US20080138833A1 (en) * 2006-12-07 2008-06-12 Wyeth Methods and compositions for assessing il-12 or the neutralization of il-12 in a sample
CA2756594C (en) * 2009-03-25 2021-03-23 Anthrogenesis Corporation Treatment of viral infection using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
KR101384203B1 (ko) * 2012-01-17 2014-04-10 공주대학교 산학협력단 개 유래의 자연살해세포의 대량 증식방법
CN104509529A (zh) * 2013-10-08 2015-04-15 康克韦斯特公司 用于储存和运输nk-92细胞系的方案和培养基
CA2926996A1 (en) * 2013-10-08 2015-04-16 Nantkwest, Inc. Protocol and media for storage and transport of nk-92 cell line
CA2927977C (en) * 2013-11-01 2024-03-05 Nantkwest, Inc. Tumoricidal and antimicrobial compositions and methods
WO2015090229A1 (en) 2013-12-20 2015-06-25 Novartis Ag Regulatable chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
CN106459916A (zh) 2014-06-18 2017-02-22 乔治-施派尔-豪斯化学疗法研究所 作为细胞治疗剂的car‑表达nk‑92细胞
WO2016014553A1 (en) 2014-07-21 2016-01-28 Novartis Ag Sortase synthesized chimeric antigen receptors
GB201501175D0 (en) 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
EP3273977A4 (de) * 2015-03-27 2018-12-05 Nantkwest, Inc. Nk-92-zellen in einer kombinationstherapie mit krebsmedikamenten
KR20180021685A (ko) 2015-04-25 2018-03-05 더 제너럴 하스피털 코포레이션 암 치료용 항-기피주성제와 항암제 조합 요법 및 조성물
KR20240013282A (ko) 2015-06-10 2024-01-30 이뮤너티바이오, 인크. 암을 치료하기 위한 변형된 nk-92 세포
CN116334205A (zh) 2015-09-03 2023-06-27 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
US10345905B2 (en) * 2015-09-08 2019-07-09 Apple Inc. Electronic devices with deformable displays
US10758567B2 (en) 2015-09-16 2020-09-01 Immune Ventures LLC In vivo priming of natural killer cells
EP3349797A4 (de) 2015-09-18 2019-06-12 The General Hospital Corporation Dba Massachusetts General Hospital Lokalisierte freisetzung von antifugetaktischem mittel zur behandlung von krebs
US11571469B2 (en) 2016-01-07 2023-02-07 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression
EP3458485B1 (de) 2016-05-19 2021-12-29 The General Hospital Corporation An den rezeptor il-2rbeta gebundenes interleukin-2, eine plattform zur erhöhung der aktivität von natürlichen killer- und regulatorischen t-zellen
KR20190049887A (ko) 2016-09-29 2019-05-09 난트케이웨스트, 인크. 감소된 면역원성을 갖는 hla 클래스 i-결핍 nk-92 세포
EP3565565A4 (de) 2017-01-04 2020-12-09 Nova Southeastern University Natürliche killerzellen (nk) zur expression eines antigenspezifischen funktionalen t-zell-rezeptor (tcr)-komplexes, verfahren zur herstellung davon und verfahren zur therapeutischen verwendung davon
EP3565889B1 (de) 2017-01-06 2025-03-26 ImmunityBio, Inc. Genetisch modifizierte nk-92-zellen mit verminderter cd96/tigit-expression
US10801013B2 (en) 2017-03-08 2020-10-13 Nantkwest, Inc. Modified NK-92 haNK003 cells for the clinic
JP2020515542A (ja) 2017-03-23 2020-05-28 ザ ジェネラル ホスピタル コーポレイション Ｃｘｃｒ４／ｃｘｃｒ７の遮断およびヒトパピローマウイルス関連疾患の治療
KR20190142775A (ko) 2017-04-19 2019-12-27 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 조작된 항원 수용체를 발현하는 면역 세포
EP3641799A1 (de) 2017-06-20 2020-04-29 Nantkwest, Inc. Kombinationstherapie aus nk-92-zellen und il-15-agonist
JP2020524164A (ja) 2017-06-20 2020-08-13 ナントクエスト インコーポレイテッド Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法
CN110997003A (zh) 2017-08-04 2020-04-10 南克维斯特公司 用nk-92细胞治疗和抑制白血病
WO2019084284A1 (en) 2017-10-27 2019-05-02 Coneksis, Inc. NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
US11446329B2 (en) 2017-11-01 2022-09-20 Restem Llc Natural killer cell adoptive transfer therapy for the elimination of senescent PBMCs, reduction of inflammatory cytokines and treatment of IBS
EP3703735A1 (de) 2017-11-01 2020-09-09 Nantkwest, Inc. Nk-92-zellen zur stimulierung von antikrebsimpfstoff
US20210040451A1 (en) 2018-01-31 2021-02-11 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
EP3743446A1 (de) 2018-03-12 2020-12-02 Nantkwest, Inc. Verwendung von cd33car-modifizierten hochaffinen nk-zellen (t-hank) zur verringerung der suppressoraktivität von myeloid-abgeleiteten suppressorzellen (oder verringerung der negativen wirkung auf die nk-zellaktivität)
WO2019182422A1 (ko) * 2018-03-23 2019-09-26 주식회사 에스엘바이젠 신규 유전자 변형 자연살해 세포주 및 그의 용도
KR20210011977A (ko) 2018-05-22 2021-02-02 난트케이웨스트, 인크. Nk-92 세포를 성장시키기 위한 기초 배지
CN119432756A (zh) 2018-05-22 2025-02-14 免疫生物公司 FC-ε CAR
KR102587512B1 (ko) 2018-05-22 2023-10-11 이뮤너티바이오, 인크. 폴록사머를 사용한 nk-92 세포 성장의 최적화
EP3797149A1 (de) 2018-05-22 2021-03-31 Nantkwest, Inc. Verfahren und systeme zur zellbettbildung während der bioverarbeitung
US20210267190A1 (en) 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
CN113164519B (zh) 2018-08-01 2025-01-10 南克维斯特公司 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
WO2020027832A1 (en) 2018-08-01 2020-02-06 Nantkwest, Inc. Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
US20210293787A1 (en) 2018-08-01 2021-09-23 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
KR20250024868A (ko) 2018-10-31 2025-02-19 난트퀘스트, 인크. Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
KR102520488B1 (ko) 2018-11-06 2023-04-10 난트퀘스트, 인크. 키메라 항원 수용체-변형된 nk-92 세포(chimeric antigen receptor-modified nk-92 cells)
WO2020112669A1 (en) 2018-11-26 2020-06-04 Nantkwest, Inc. Il-2 dependent nk-92 cells with stable fc receptor expression
WO2020180744A1 (en) * 2019-03-01 2020-09-10 The Regents Of The University Of California Natural killer cell induced cellular vesicles for cancer therapy
US12085571B2 (en) 2019-06-13 2024-09-10 Immunitybio, Inc. Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
AU2019459423B2 (en) 2019-08-01 2023-06-01 Immunitybio, Inc. Anti-B7-H4 chimeric antigen receptor-modified NK-92 cells
US20220333079A1 (en) * 2019-09-18 2022-10-20 Slbigen Inc. Genetically modified nk cell line transduced with gene encoding novel chimeric antigen receptor and use thereof
GB2604813B (en) 2019-11-20 2025-03-05 Immunitybio Inc Cell-mediated transient delivery of immune-enhancing molecules into the tumor microenvironment
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
US20240415964A1 (en) 2021-11-02 2024-12-19 Immunitybio, Inc. Natural killer cells for chordoma therapy

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE25609E (en) * 1964-06-30 Fiber-blending apparatus
US3111857A (en) * 1959-12-03 1963-11-26 Fiber Controls Corp Speed change mechanism
US2995783A (en) * 1959-12-03 1961-08-15 Kenneth G Lytton Apparatus for feeding textile fibers in a uniform stream
US3142348A (en) * 1961-06-14 1964-07-28 Fiber Controls Corp Fiber feeding apparatus
US3196967A (en) * 1961-07-05 1965-07-27 Kenneth G Lytton Weighing mechanism
US3132709A (en) * 1961-07-05 1964-05-12 Fiber Controls Corp Apparatus for feeding textile fibers in a uniform stream
US3671078A (en) * 1962-07-15 1972-06-20 Fiber Controls Corp Material distributing system
US3901555A (en) * 1962-07-15 1975-08-26 Fiber Controls Corp Material distributing system
US3225848A (en) * 1962-11-19 1965-12-28 Fiber Controls Corp Automatic control system for blending equipment
US3308786A (en) * 1963-07-08 1967-03-14 Fiber Controls Corp Fiber liquid treatment system
US3355773A (en) * 1964-07-08 1967-12-05 Fiber Controls Corp Oscillatable fiber rake
US3421659A (en) * 1967-08-14 1969-01-14 Kenneth G Lytton Fiber feeding apparatus
US3659279A (en) * 1969-06-27 1972-04-25 Fiber Controls Corp Default warning system
US3700091A (en) * 1971-01-29 1972-10-24 Fiber Controls Corp Fiber transporting device
US3918539A (en) * 1972-10-06 1975-11-11 Fiber Controls Corp Weighing system
US4638875A (en) * 1984-12-24 1987-01-27 Fiber Controls Corp. Blending system weighing unit
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5574205A (en) * 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US8211422B2 (en) * 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US5702702A (en) * 1992-03-30 1997-12-30 The Wistar Institute Of Anatomy And Biology Modified cytotoxic tall cell line and compositions and methods for manufacture and use thereof as therapeutic reagents for cancer
US5272082A (en) * 1992-03-30 1993-12-21 The Wistar Institute Of Anatomy & Biology Cytotoxic T-ALL cell lines and uses therefor
CA2162732C (en) 1993-05-14 2007-01-09 Daniela Santoli Use of modified tall-104 cells to treat cancer and viral diseases
US5665588A (en) * 1993-09-24 1997-09-09 Univ Arkansas DNA encoding natural killer lytic associated protein
US5772995A (en) * 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
US6022538A (en) * 1995-06-06 2000-02-08 The Wistar Institute Of Anatomy And Biology Method of treating malignancies

Also Published As

Publication number Publication date
US20020068044A1 (en) 2002-06-06
AU7267398A (en) 1998-11-24
US20040018183A1 (en) 2004-01-29
US20060110360A1 (en) 2006-05-25
US10138462B2 (en) 2018-11-27
EP1007630A1 (de) 2000-06-14
DE69834257T2 (de) 2007-01-04
WO1998049268A1 (en) 1998-11-05
EP1690927A1 (de) 2006-08-16
EP1007630B1 (de) 2006-04-19
US20040022773A1 (en) 2004-02-05
ES2263205T3 (es) 2006-12-01
WO1998049268A9 (en) 1999-03-25
US20040018182A1 (en) 2004-01-29
DE69834257D1 (de) 2006-05-24
EP1007630A4 (de) 2001-08-16

Similar Documents

Publication Publication Date Title
ATE323756T1 (de) Natürliche killerzelllinien und verfahren zu ihrer verwendung
Unger et al. In vitro expression of the endothelial phenotype: comparative study of primary isolated cells and cell lines, including the novel cell line HPMEC-ST1. 6R
Bianco et al. Bone marrow stromal stem cells: nature, biology, and potential applications
Reyes et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells
US5639618A (en) Method of isolating a lineage specific stem cell in vitro
Martínez-Serrano et al. Human neural stem and progenitor cells: in vitro and in vivo properties, and potential for gene therapy and cell replacement in the CNS
WO1997012960A3 (en) Solid support for use in cell cultivation, especially for the cultivation of liver cells, biological reactor containing said solid support and the use thereof in a bio-artificial liver system
RU2010112393A (ru) СТИМУЛЯЦИЯ ПУТИ Wnt ПРИ ПЕРЕПРОГРАММИРОВАНИИ СОМАТИЧЕСКИХ КЛЕТОК
ATE184647T1 (de) Embryonische stammzelle zur herstellung von chimäre und transgen-ongulaten
ATE320479T1 (de) Process zur verwendung des obese-gens und seines genprodukts zur stimulierung der entwicklung von haemotopoietischen zellen
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
DE3280479D1 (de) Rekombinante DNS-Mittel und Verfahren
ATE296875T1 (de) Verfahren zur herstellung von genetisch modifizierten cd34-negativen, adhärent wachsenden hämatopoietischen stammzellen
Zipori The stem state: mesenchymal plasticity as a paradigm
ES2191324T3 (es) Proteinas fluorescentes como marcadores especificos de tipos celulares.
WO2016117816A1 (ko) 인간 중간엽 줄기세포의 줄기세포능을 증가시키는 방법
Jeker et al. Mouse thyroid primary culture
Guasch et al. Mice in the world of stem cell biology
Matsumura et al. Establishment of integration-free induced pluripotent stem cells from human recessive dystrophic epidermolysis bullosa keratinocytes
AU643672B2 (en) Process for the introduction of exogenous DNA in somatic and germ animal cells
DE3855634D1 (de) Innerhalb des alpha-Locus gelegenes T-Zell-Rezeptor-Gen und DNA-Konstruktionen
Avots et al. Plasticity of hematopoietic stem cells and cellular memory
EP0808364A4 (de) Menschliche pancreas zellinien: entwiklungen und anwendungen
Neumeister et al. Neural progenitors of the postnatal and adult mouse forebrain retain the ability to self-replicate, form neurospheres, and undergo multipotent differentiation in vivo
Bosch et al. Cloned interstitial stem cells grow as contiguous patches in hydra

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1007630

Country of ref document: EP

EEIH Change in the person of patent owner